With few exceptions, 2009 pandemic influenza A (H1N1) virus strains that began circulating in April 2009 remained sensitive to oseltamivir (16).CDC's Advisory Committee on Immunization Practices (ACIP) provides annual recommendations for the prevention and control of influenza.
Office of the Associate Director for Science, Office of the Director The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; the Influenza Division, Nancy Cox, Ph D, Director; the Office of the Associate Director for Science, Harold Jaffe, MD, Director; the Immunization Safety Office, Division of Healthcare Quality Promotion, Denise Cardo, MD, Director; and the Immunization Services Division, Lance Rodewald, MD, Director. The 2010 influenza recommendations include new and updated information.
Corresponding preparer: Timothy Uyeki, MD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, N. Telephone: 404-639-3747; Fax: 404-639-3866; E-mail: [email protected] This report updates the 2009 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for the prevention and control of influenza (CDC. Use of influenza A (H1N1) 2009 monovalent vaccine---recommendations of the Advisory Committee on Immunization Practices [ACIP], 2009. Highlights of the 2010 recommendations include 1) a recommendation that annual vaccination be administered to all persons aged ≥6 months for the 2010--11 influenza season; 2) a recommendation that children aged 6 months--8 years whose vaccination status is unknown or who have never received seasonal influenza vaccine before (or who received seasonal vaccine for the first time in 2009--10 but received only 1 dose in their first year of vaccination) as well as children who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine regardless of previous influenza vaccine history should receive 2 doses of a 2010--11 seasonal influenza vaccine (minimum interval: 4 weeks) during the 2010--11 season; 3) a recommendation that vaccines containing the 2010--11 trivalent vaccine virus strains A/California/7/2009 (H1N1)-like (the same strain as was used for 2009 H1N1 monovalent vaccines), A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens be used; 4) information about Fluzone High-Dose, a newly approved vaccine for persons aged ≥65 years; and 5) information about other standard-dose newly approved influenza vaccines and previously approved vaccines with expanded age indications.
Recommendations for influenza diagnosis and antiviral use will be published before the start of the 2010--11 influenza season.
Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information.
Work Group members also request periodic updates on vaccine and antiviral production, supply, safety, and efficacy from vaccinologists, epidemiologists, and manufacturers.